New paper suggests that tumor cells may develop resistance to potential Ras inhibitors

April 17, 2018, The National Centre for Cancer Research

Researchers have long sought a treatment aimed specifically at the Ras family of genes, the most common oncogenes and those that initiate many of the most lethal tumours. However, the results of a hypothetical treatment may be far less positive than speculated, according to a manuscript published in Genes & Development by the Genomic Instability Group at the Spanish National Cancer Research Centre (CNIO). The study shows that cells are capable of surviving even in the total absence of Ras genes if another gene, Erf, is also lost.

Discovered in 1982 by Mariano Barbacid's group, among others, alterations in Ras genes were the first mutation described in cancer. This was a paradigm-shifting discovery, revealing for the first time that tumours are initiated by mutations in genes, thereby raising hope that inhibitors for these mutated genes could cure cancer. "It is the basis of personalised medicine," explains Óscar Fernández-Capetillo, leader of this work.

Mutations in Ras genes lead to the most lethal tumours, including lung, pancreas and colon cancer. Therefore, developing a RAS pharmacological inhibitor has frequently been described as the search for the Holy Grail in the battle against cancer, in which billions have been invested. However, achieving an inhibitor for RAS proteins is complicated due mainly to their three-dimensional structure, similar to a sphere, which makes it difficult to generate pharmaceuticals that inhibit their activity. As an alternative to treating these tumours, pharmaceuticals have been developed that attack the other members of the Ras route, such as inhibitors of MEK, RAF and EGFR.

"Personalised medicine, in spite of its success stories, has an Achilles heel in the fact that tumours have dozens or even hundreds of mutations, so while treatments generally work for a limited time, tumours invariably end up developing resistance due to another mutation," says Fernández-Capetillo.

Although therapies against the RAS route constitute an important part of current antitumoral strategies, the search for RAS inhibitors continues "despite the fact that it is not clear if tumours are not going to be capable of developing resistance to these treatments," says Sergio Ruiz, co-leader of the study. "In our work, we show that it is even possible to develop teratomas (a type of germinal ) lacking all RAS genes, if the tumour also lacks ERF expression."

ERF loss rescues the effects of RAS deficiency

The main role of RAS proteins consists of translating external growth signals (nutrients, growth factors, etc.) into proliferating responses within the cell. When RAS proteins are eliminated in mouse stem cells, these remain in a sort of suspended state—they do not grow, they do not differentiate into other cell types and are not capable of forming tumours.

Cristina Mayor-Ruiz, first author of the study, initially observed that certain tumour cells were capable of growing even in the absence of serum, if the gene Erf was also eliminated. Fernández-Capetillo explains "For me, this discovery was the origin of the project as it made us speculate that if cells can grow with hardly any nutrients upon eliminating ERF, this could even allow the growth of RAS-free cells." This hypothesis turned out to be correct—eliminating ERF allows mouse embryonic stem to grow, differentiate and even generate tumours in total absence of RAS genes.

The study also explains the mechanism by which ERF restricts the action of RAS proteins. In the absence of RAS, ERF is recruited to the regulating areas ("enhancers") of multiple genes, modulating their function, which ultimately limits cell growth. "ERF is a kind of brake that limits the consequences of RAS activation," indicates Cristina Mayor-Ruiz.

"The message is not good, but its knowledge is important for cancer research and personalised medicine," says Fernández-Capetillo. "Although a perfect inhibitor of RAS has been achieved, tumours may be capable of resistance to the treatment, accumulating mutations in like ERF." In fact, recent studies have found ERF mutations in cancer patients, indicating that this situation may, indeed, exist in the clinic. Therefore, Fernández-Capetillo's group is now exploring whether in ERF can account for the resistance to personalised therapies against inhibitors of the RAS route.

Explore further: 'Cell' article reveals new resistance mechanism to chemotherapy in breast and ovarian cancer

More information: Cristina Mayor-Ruiz et al, ERF deletion rescues RAS deficiency in mouse embryonic stem cells, Genes & Development (2018). DOI: 10.1101/gad.310086.117

Related Stories

'Cell' article reveals new resistance mechanism to chemotherapy in breast and ovarian cancer

June 18, 2013
It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumours are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2. In ...

Scientists discover a new mechanism of resistance to chemotherapy

April 7, 2016
The occurrence of chemotherapy resistance is one of the major reasons for failure in cancer treatment. A study led by Óscar Fernández-Capetillo, Head of the Genomic Instability Group at the Spanish National Cancer Research ...

ATR inhibitors prove effective in two pre-clinical models of cancer

September 13, 2016
Tumours are an accumulation of cells that divide without control, accumulating hundreds of chromosomal alterations and mutations in their DNA. These alterations are triggered in part by a type of damage to the DNA known as ...

Genes activated in metastasis also drive the first stages of tumour growth

February 21, 2018
In spite of the difference between the cell functions responsible for giving rise to a tumour and that give rise to metastasis, studies at IRB Barcelona using the fly Drosophila melanogaster reveal that some genes can drive ...

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Gene known to protect against cancer can also promote tumor growth: study

March 13, 2012
Can a gene simultaneously protect against cancer and favor its growth? Researchers at the Spanish National Cancer Research Centre have discovered a gene with this double-edged property and suspect there may be many more that ...

Recommended for you

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.